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ABSTRACT
Introduction Systemic sclerosis (SSc) is a chronic, 
autoimmune connective tissue disease associated with high 
morbidity and mortality, especially in diffuse cutaneous SSc 
(dcSSc). Currently, there are several treatments available 
in early dcSSc that aim to change the disease course, 
including immunosuppressive agents and autologous 
haematopoietic stem cell transplantation (HSCT). HSCT 
has been adopted in international guidelines and is offered 
in current clinical care. However, optimal timing and 
patient selection for HSCT are still unclear. In particular, it 
is unclear whether HSCT should be positioned as upfront 
therapy or rescue treatment for patients refractory to 
immunosuppressive therapy. We hypothesise that upfront 
HSCT is superior and results in lower toxicity and lower 
long- term medical costs. Therefore, we propose this 
randomised trial aiming to determine the optimal treatment 
strategy for early dcSSc by comparing two strategies used 
in standard care: (1) upfront autologous HSCT versus (2) 
immunosuppressive therapy (intravenous cyclophosphamide 
pulse therapy followed by mycophenolate mofetil) with 
rescue HSCT in case of treatment failure.
Methods and analysis The UPSIDE (UPfront 
autologous hematopoietic Stem cell transplantation vs 
Immunosuppressive medication in early DiffusE cutaneous 
systemic sclerosis) study is a multicentre, randomised, 
open- label, controlled trial. In total, 120 patients with early 
dcSSc will be randomised. The primary outcome is event- 
free survival at 2 years after randomisation. Secondary 
outcomes include serious adverse events, functional status 
and health- related quality of life. We will also evaluate 
changes in nailfold capillaroscopy pattern, pulmonary 
function, cardiac MR and high- resolution CT of the chest. 
Follow- up visits will be scheduled 3- monthly for 2 years 
and annually in the following 3 years.
Ethics and dissemination The study was approved by 
the Dutch Central Committee on Research Concerning 
Human Subjects (NL72607.041.20). The results will 
be disseminated through patient associations and 
conventional scientific channels.
Trial registration numbers NCT04464434; NL 8720.
INTRODUCTION
Systemic sclerosis (SSc) is a debilitating and 
incurable autoimmune connective tissue 
disease. Clinical features include vasculopathy, 
fibrosis and inflammation of skin and internal 
organs.1 Presentation and disease course are 
very heterogeneous. In the diffuse cutaneous 
subset of SSc (dcSSc), there is generalised 
skin thickening and often multiorgan involve-
ment.2–4 Due to its progressive character, the 
median 5- year and 12- year mortality for dcSSc 
is ~25% and 70%, respectively.5 6 To prevent 
progression and death in patients with SSc, it 
is key to identify individuals at risk at an early 
stage of the disease and initiate immunomod-
ulating treatment. Methotrexate, mycopheno-
late mofetil (MMF) and cyclophosphamide 
Strengths and limitations of this study
 ► This study is a multicentre, randomised, controlled, 
open- label trial aiming to determine whether upfront 
autologous stem cell transplantation (HSCT) is supe-
rior to standard immunosuppressive treatment (with 
rescue HSCT for those who progress) in early diffuse 
cutaneous systemic sclerosis (dcSSc).
 ► Event- free survival is the primary outcome measure 
and is defined as the time in days from randomis-
ation until death due to any cause or the develop-
ment of persistent major organ failure (heart, lung 
or kidney).
 ► This clinical trial has the potential to change clinical 
practice in early dcSSc worldwide
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(CYC) are commonly used in dcSSc, dependent on the 
organ system involved.
In three randomised controlled trials in dcSSc, treatment 
with autologous haematopoietic stem cell transplantation 
(HSCT) improved survival, quality of life and skin fibrosis 
and prevented disease progression when compared with 
CYC pulse therapy.7–9 In addition, three systematic reviews 
were published on the efficacy and safety of HSCT in 
SSc.10–12 In all reviews, it was concluded that HSCT provided 
a survival benefit, improved skin involvement and stabi-
lised pulmonary function compared with intravenous CYC 
for 12 months. Heterogeneity between studies, however, 
prevented meta- analysis, yet a trend towards better outcome 
was observed in patients with a shorter disease duration 
before HSCT. HSCT has since been implemented in (inter)
national treatment guidelines for SSc, made its way into 
regular clinical care and is reimbursed in several European 
countries.13 14 However, recommendations regarding the 
optimal use and especially the preferred timing of HSCT 
and the efficacy of other therapies in the course of dcSSc 
are lacking. Particularly, it is unclear whether HSCT should 
be positioned as upfront or as rescue treatment for patients 
not responding to immunosuppressive therapy such as 
MMF or intravenous pulse CYC.
HSCT as upfront treatment might result in better 
outcomes because the disease process is effectively targeted 
early in the disease at a time when there is less irreversible 
organ damage. On the other hand, HSCT is a treatment 
associated with a higher risk of adverse events compared 
with other treatments, as it is associated with a treatment- 
related mortality of approximately 10%.8 15 Even so, there 
might be fewer transplant- related adverse events due to the 
better health status of patients and limited immunosuppres-
sive premedication if HSCT is commenced early, compared 
with the patients who need rescue HSCT after months or 
even years of other immunocompromising agents. So to 
determine the optimal treatment strategy in early dcSSc, 
further investigation is needed.
This article describes the protocol of the UPSIDE 
(UPfront autologous hematopoietic Stem cell transplan-
tation vs Immunosuppressive medication in early DiffusE 
cutaneous systemic sclerosis) study. The UPSIDE study is a 
multicentre, randomised, open- label, controlled trial that 
aims to compare two treatment strategies used in standard 
care of adult patients with early dcSSc: upfront autologous 
HSCT versus intravenous CYC pulse therapy, followed by 
oral MMF and rescue HSCT in case of treatment failure. Effi-
cacy, safety, survival and cost- effectiveness will be evaluated.
Aims and objectives
The UPSIDE study aims to investigate the optimal 
timing of HSCT in early dcSSc by comparing two treat-
ment strategies: the effect of HSCT as upfront therapy 
compared with that of immunosuppressive medication 
and HSCT in case of failure, with respect to (event- 
free) survival and prevention of major organ failure, 
safety and the impact on skin thickening, visceral 
involvement, functional status and quality of life. 
 Secondary goals are to evaluate (in both treatment arms) 
whether disease activity correlates with immunological 
parameters, including immunopathology of skin, immune 
reconstitution and autoantibodies. Cost- effectiveness 
of both therapeutic options and factors associated with 
response to treatment will also be examined.
METHODS AND ANALYSIS
This protocol has been developed in accordance with the 
Standard Protocol Items: Recommendations for Inter-
ventional Trials 2013 statement (https://www. spirit- state-
ment. org/).
Study design and setting
The UPSIDE study is a randomised, 
controlled, multicentre, open- label trial. 
SSc is a rare condition, and stem cell mobilisation after 
intravenous CYC administration and HSCT are treat-
ments only performed in experienced tertiary treatment 
centres. Therefore, national and international collabora-
tion is of key importance to include the necessary number 
of patients. Participants will be recruited from 15 partici-
pating centres from the Netherlands, Belgium, Germany, 
Italy, Sweden, Switzerland and Croatia (table 1). Multidis-
ciplinary expert teams in the field of SSc and HSCT are 
involved in each centre.
Study population and eligibility criteria
We will include 120 patients with early dcSSc who fulfil the 
inclusion criteria (table 2). These criteria are designed to 
select patients in an early stage of the disease, but at high 
risk of disease progression and subsequent death. Baseline 
Table 1 Participating centres
Country Centres and affiliated networks
The Netherlands Amsterdam UMC
Leiden University Medical Centre
Radboudumc Nijmegen
University Medical Centre Utrecht 
(coordinating centre)
National scleroderma network: Arthritis 
Research and Collaboration Hub (ARCH)
Belgium University Hospital Ghent
University Hospital Leuven
National scleroderma network: Belgian 
Scleroderma Cohort




Sweden Karolinska University Hospital 
Stockholm
Skåne University Hospital Lund
Switzerland University Hospital Basel
Italy ASST G.Pini- CTO, Milano
Croatia University Hospital Zagreb
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assessment prior to randomisation includes complete blood 
count, liver function, kidney function, urine spot test 
(protein/creatinine ratio), viral serology tests, 12- lead ECG, 
cardiac ultrasound, cardiac MR, right heart catheterisation, 
high- resolution CT of the chest and pulmonary function 
tests. Patient recruitment started in September 2020. We 
anticipate the accrual time will be 3 years. Patients will be 
followed for 5 years.
Randomisation
Eligible patients who provide informed consent will be 
randomised 1:1 (variable block randomisation) using 
the validated algorithm within CASTOR, the Electronic 
Data Capture program used for the study. Blocks of two, 
four or six patients will be randomly and blindly assigned, 
stratified by the participating centre. The two treatments 
are as follows: strategy arm A—upfront high- dose non- 
myeloablative autologous HSCT or strategy arm B—
intravenous pulse therapy with CYC followed by at least 
12 months of oral MMF daily and thereafter HSCT as 
rescue option. The treatment allocation will be coordi-
nated by the principal investigator of the study site. The 
investigators and participants are not blinded to treat-
ment allocation.
Interventions
Arm A: Upfront autologous HSCT
Autologous, non- myeloablative HSCT comprises the 
following consecutive steps:
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age between 18 and 65 years Pregnancy or unwillingness to use adequate contraception during study
Fulfilling the 2013 ACR- EULAR classification criteria for dcSSc Poor compliance of the patient as assessed by the referring physician
Disease duration ≤2 years (from onset of first non- Raynaud’s 
symptoms)
 ► mRSS ≥15 (diffuse skin pattern) and/or
 ► Clinically significant organ involvement as defined by either:
 – Respiratory involvement =
 – DLco and/or (F)VC ≤85% (of predicted) and evidence 
of interstitial lung disease on HR- CT scan with 
clinically relevant obstructive disease and emphysema 
excluded
 – Patients with a DLco and/or FVC >85%, but with 
a progressive course of lung disease: defined as 
relative decline of >10% in FVC predicted and/or 
TLC predicted, or >15% in DLco predicted within 
12 months. Intercurrent infections excluded
 – Renal involvement=any of the following criteria: 
hypertension (two successive BP readings of either 
systolic ≥160 mm Hg or diastolic >110 mm Hg, at least 
12 hours apart), persistent urinalysis abnormalities 
(proteinuria, haematuria, casts), microangiopathic 
haemolytic anaemia, new renal insufficiency (serum 
creatinine>upper limit of normal); non- scleroderma- 
related causes (eg, medication, infection) must be 
reasonably excluded
 – Cardiac involvement=any of the following criteria: 
reversible congestive heart failure, atrial or ventricular 
rhythm disturbances such as atrial fibrillation or flutter, 
atrial paroxysmal tachycardia or ventricular tachycardia, 
second- degree or third- degree AV block, pericardial 
effusion (not leading to haemodynamic problems), 
myocarditis; non- scleroderma- related causes must have 
been reasonably excluded
Concomitant severe disease=
 ► Respiratory: resting mPAP >20 mm Hg (by right heart catheterisation), 
DLco <40% predicted, respiratory failure as defined by the primary end 
point
 ► Renal: creatinine clearance <40 mL/min (measured or estimated)
 ► Cardiac: clinical evidence of refractory congestive heart failure; 
LVEF <45% by cardiac echo or cardiac MR; chronic atrial fibrillation 
necessitating oral anticoagulation; uncontrolled ventricular arrhythmia; 
pericardial effusion with haemodynamic consequences16
 ► Liver failure as defined by a sustained threefold increase in serum 
transaminase or bilirubin, or Child- Pugh score C
 ► Psychiatric disorders including active drug or alcohol abuse
 ► Concurrent neoplasms or myelodysplasia
 ► Bone marrow insufficiency defined as leukocytopenia <4.0×109/L, 
thrombocytopenia <50×109/L, anaemia <80 g/L, CD4+ T lymphopenia 
<200×106/L
 ► Uncontrolled hypertension
 ► Uncontrolled acute or chronic infection, including HIV and HTLV-1,2 
positivity





Previous treatments with immunosuppressants >6 months, including 
mycophenolate mofetil, methotrexate, azathioprine, rituximab, tocilizumab 
and glucocorticoids
Previous treatments with TLI, TBI or alkylating agents including 
cyclophosphamide
Significant exposure to bleomycin, tainted rapeseed oil, vinyl chloride, 
trichlorethylene or silica
Eosinophilic myalgia syndrome, eosinophilic fasciitis, morphea
ACR- EULAR, American College of Rheumatology/European League Against Rheumatism; AV, atrioventricular; BP, blood pressure; dcSSC, diffuse 
cutaneous systemic sclerosis; DLco, diffusing capacity for carbon monoxide; ECOG, Eastern Cooperative Oncology Group; FVC, forced vital 
capacity; HR- CT, high- resolution CT; HTLV, human T- lymphotropic virus; LVEF, left ventricular ejection fraction; mPAP, mean pulmonary artery 
pressure; mRSS, modified Rodnan skin score; TBI, total body irradiation; TLC, total lung capacity; TLI, total lymphoid irradiation.
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A. Mobilisation: Peripheral blood stem cells (PBSCs) will 
be mobilised using a regimen consisting of infusion of 
CYC 2 g/m2 for 1 day. Hyperhydration, alkalinisation 
of the urine and Mesna will be given to prevent hae-
morrhagic cystitis. The patients will receive filgrastim 
(granulocyte colony- stimulating factor) 5 µg/kg/day 
subcutaneously once or twice a day for 5 days (or more 
when necessary), according to local practice.
B. Leukapheresis: Start of leukapheresis is required at a 
CD34+ cell count of ≥10–20/µL, according to local 
practice. This is expected to occur on day 5 or day 
6 of filgrastim treatment. Leukaphereses will be per-
formed with the goal to obtain at least 6×106 CD34+ 
cells/kg body weight. The primary goal is to obtain a 
target dose of 6×106 CD34+ cells/kg, with a minimum 
of 2×106 CD34+ cells/kg after CD34 selection. The 
apheresis product will be 4-5log T- cell depleted. The 
CD34+ -selected cells will be cryopreserved and stored 
in liquid nitrogen until reinfusion. In case of mobilisa-
tion failure, the patient will be treated with daily sub-
cutaneous injection of filgrastim 20 µg/kg.
C. Prior to conditioning: Echocardiography, troponin 
and N- terminal pro- brain natriuretic peptide (NT- 
proBNP) should be repeated prior to conditioning 
to evaluate possible subclinical cardiac toxicity caused 
by CYC administered during mobilisation. Condition-
ing can be initiated if left ventricular ejection fraction 
(LVEF) is >45% or has not decreased with >15% com-
pared with premobilisation, and there are no uncon-
trolled arrhythmias.16
D. Conditioning: Conditioning is to be initiated preferably 
within 6 weeks after successful harvest. The condition-
ing regimen consists of CYC 50 mg/kg/day intrave-
nously for 4 consecutive days (total 200 mg/kg) and 
rabbit antithymocyte globulin (rbATG, Thymoglobu-
lin). The first dose of CYC will be given on day −5 (day 
0=day of infusion of PBSC). Hyperhydration, alkalin-
isation of the urine and Mesna will be given to pre-
vent haemorrhagic cystitis. A total dose of 7.5 mg/kg 
intravenous rbATG will be administered over 3 days. 
Intravenous methylprednisolone 2 mg/kg will be giv-
en on the days rbATG will be administered to improve 
tolerability of the ATG.
E. Peripheral stem cell infusion: The interval between the 
last dose of CYC and infusion of the graft will be at 
least 48 hours. On day 0, CD34+ -selected stem cells 
are thawed and infused according to local standard 
operating procedures. The number of CD34+ cells to 
be reinfused should be ≥2.0×106/kg, and residual T- 
cell content is targeted at ≤1.0×105 T cells/kg, calcu-
lated before freezing.17 Exceptional release according 
to local practice is allowed and will be registered in the 
electronic case report form.
Arm B: CYC followed by MMF and HSCT as rescue 
option
Immunosuppressive therapy in arm B consists of 
12- monthly intravenous pulses of CYC 750 mg/m2 (=9 g/
m2 cumulative) followed by at least 12 months of oral 
MMF daily (3 g as maximum daily dosage) or mycophe-
nolic acid (up to 2.160 g daily), according to local prac-
tice. Hyperhydration, alkalinisation of urine and Mesna 
are recommended during 12- monthly intravenous pulses 
of CYC and will be given according to local protocols to 
prevent haemorrhagic cystitis.
Supportive care
Supportive care measures, including prophylactic or ther-
apeutic antibiotics, antiviral or antifungal agents, transfu-
sions and antiemetic agents, will be taken according to 
local standard operating procedures for such patients. In 
case of HSCT, particular attention will be paid to the risk 
of Epstein- Barr virus (EBV) and cytomegalovirus (CMV) 
reactivation. EBV and CMV load will be monitored by 
PCR, weekly in the first 3 months following the transplan-
tation and then monthly for the next 9 months. In case 
of reactivation, the patient will be treated according to 
standard of care guidelines.
Initiation of an ACE- inhibitor prior to HSCT is strongly 
recommended (ie, enalapril 5 mg once a day) to prevent 
scleroderma renal crisis based on the clinical experience 
from the Autologous Stem cell Transplantation Interna-
tional Scleroderma (ASTIS) trial.8 Monitoring of blood 
potassium levels after initiation of ACE- inhibitors is recom-
mended, especially when combined with co- trimoxazole.
Study outline
An overview of the study outline is shown in figure 1 (study 
flow diagram). After randomisation, concurrent immuno-
suppressive therapy will be discontinued. Glucocorticoids 
may be continued at the lowest possible dose. Either treat-
ment is to be initiated within 6 weeks after randomisation, 
that is, mobilisation in patients randomised to arm A and 
the first pulse of CYC in patients randomised to arm B.
Rescue therapy may be considered in both arms in case 
of insufficient response or clinically relevant flare, but 
preferably not within the first 6 months after randomis-
ation. For patients from arm A, methotrexate, MMF or 
mycophenolic acid, or rituximab can be (re)instituted, 
according to local preference. Based on earlier studies, 
the clinical benefits of intravenous pulse CYC may take 
between 6 months and 12 months. Therefore, it is recom-
mended to then switch patients from arm B to HSCT only 
in case of rapidly progressive disease, which is arbitrarily 
defined as ≥30% increase in modified Rodnan skin score 
(mRSS) or ≥20% relative decline in forced vital capacity 
(FVC), total lung capacity (TLC), or diffusion capacity for 
carbon monoxide (DLco) predicted.
Outcomes and follow-up
The primary end point of the study will be event- free 
survival. Event- free survival is defined as the time in days 
from the day of randomisation until the occurrence of 
death due to any cause or the development of persistent 
major organ failure (heart, lung, kidney) defined as 
follows:
 ► Heart: LVEF <30% by cardiac MR (or cardiac echo).
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 ► Lungs: respiratory failure=resting arterial oxygen 
tension <8 kPa (<60 mm Hg) and/or resting arterial 
carbon dioxide tension >6.7 kPa (>50 mm Hg) without 
oxygen supply or need of oxygen supply.
 ► Kidney: need for renal replacement therapy (ie, 
dialysis)
Secondary outcome measures include the following:
1. Progression- free survival, defined as the time in days 
since the day of randomisation until any of the fol-
lowing relative changes from baseline has been docu-
mented: death, ≥10% drop in (F)VC predicted and/or 
≥15% drop in DLco predicted,18 ≥15% drop in LVEF 
by echo or cardiac MR, ≥15% drop in body weight, 
≥30% drop in creatinine clearance, ≥25% and >5- point 
increase in skin score and ≥0.5 increase in Scleroderma 
Health Assessment Questionnaire (SHAQ).
2. Treatment- related mortality, defined as any death 
during the study period following randomisation that 
cannot be attributed to progression of the disease ac-
cording to the consensus opinion of the Data and Safe-
ty Monitoring Board (DSMB).
3. Overall survival.
4. Treatment toxicity and adverse events, using WHO 
toxicity parameters (≥grade 3 toxicity) and BMT- CTN 
(Bone Marrow Transplant Clinical Trials Network, for 
viral infections) during the study period.
5. The area under the curve (AUC) of the combined re-
sponse index for systemic sclerosis (CRISS) over time, 
measuring the ‘predicted probability of being im-
proved’ over 2 years. This AUC is calculated based on 
four repeated measures (6, 12, 18 and 24 months) with 
back- translation to the original scale between 0 and 1.
6. The change from baseline over time (ie, during follow- 
up) of the following parameters: mRSS; pulmonary 
involvement: DLco and DLco/VA, (F)VC, TLC, resid-
ual volume, mean pulmonary artery pressure by cardi-
ac echo (or right heart catheterisation), lung density 
measurement by thoracic CT and fluorine-18 fluoro-
deoxyglucose positron emission tomography scan of 
lung; renal involvement: urine spot test—creatinine/
protein ratio; myocardial involvement: left ventricu-
lar function as measured by cardiac MR; body weight 
(kg); changes in nailfold capillaroscopy; changes in 
modified Hand Mobility in Scleroderma (functional 
assessment of hand function); quality of life (EuroQol 
five dimensions five levels); SHAQ including visual an-
alogue scale for scleroderma- specific symptoms; gas-
trointestinal symptom scale (University of California, 
Los Angeles Scleroderma Clinical Trial Consortium 
Gastrointestinal Tract Instrument 2.0); sexual func-
tioning (International Index of Erectile Function-15 
questionnaire (in men) and Sexual Functioning 
Figure 1 Study flow diagram. ATG, anti- thymocyte globulin; CYC, cyclophosphamide; HSCT, haematopoietic stem cell 
transplantation; MMF, mycophenolate mofetil.
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Questionnaire-28 (in women)); fatigue score 
(Functional Assessment of Chronic Illness Therapy 
questionnaire); self- assessment of skin (Patient self- 
Assessment of Skin Thickness in Upper Limb); pro-
ductivity losses due to health issues (customised 
iProductivity Cost Questionnaire questionnaire); and 
characteristics of the immune system: autoantibody 
concentration and avidity targeting host nuclear an-
tigens, primarily focusing on anti- topoisomerase and 
anti- RNA polymerase III antibodies (ATA and ARA) ; 
isotype usage; isotype levels; Fc- glycosylation profiles of 
anti- topoisomerase and skewing of T- cell receptor rep-
ertoire and determination of human leukocyte antigen 
profiles; inflammatory and fibrotic characteristics of 
the skin; and levels of ATG in relation to changes in 
lymphocyte subsets and outcomes.
Follow- up appointments will be according to regular 
care: monthly the first half year, then 3- monthly until 
2 years after randomisation, followed by annual appoint-
ments for 3 years (table 3).
Statistical analyses
Sample size
The sample size is determined assuming a median 
event- free survival of 2 years in the control group and an 
(approximate) exponential survival curve based on the 
survival observed in the HSCT arm of the ASTIS trial.7 We 
expect our proposed intervention to result in a consider-
able improvement (assumed HR of 0.5) and take a total 
study period of 5 years (3 years for recruiting patients at a 
constant rate), 10% loss to follow- up after 5 years in both 
groups and an alpha of 0.05 into account. Based on the 
above, we will need 60 patients per group to have at least 
80% power to detect a difference as calculated using the 
SAS power procedure (two- sample survival, log- rank test). 
Based on the incidence of dcSSc and the collective treat-
ment experience of the 15 trial sites, we anticipate we can 
enrol the required 120 patients (60 per group) within 
3 years.19 20
Primary outcome
Data will be analysed on an intention- to- treat (ITR) basis. 
Data regarding adverse events and serious adverse events 
will be provided using descriptive statistics and tables. 
Population characteristics will be provided using descrip-
tive statistics. To compare event- free survival (the primary 
end point) and other time- to- event outcomes between 
treatment groups, Kaplan- Meier (KM) curves will be 
constructed (based on first event) and tested using the 
log- rank test and Cox regression to take important prog-
nostic covariates (sex, age, smoking status, cardiac func-
tion) and centre (stratification factor for randomisation), 
as determined a priori (before database lock) in SAP, 
into account. For all time- to- event outcomes, data are 
censored at the last visit. Based on a visual inspection of 
the KM curves, also a treatment×time interaction will be 
modelled in the Cox regression analysis to allow for non- 
constant hazards over time. An ITT analysis (primary) 
and per- protocol (PP) analysis will be performed. In the 
primary analysis for patients leaving the study early (early 
dropout), this last visit will be treated as the censoring 
date, and a multiple imputation method for sensitivity 
analyses of time- to- event data accounting for possible 
informative censoring will also be performed.
Secondary outcomes
Secondary continuous outcomes (ie, change from base-
line in CRISS score)21 measured over time will be anal-
ysed using mixed modelling approaches, if needed, based 
on graphical inspection including a treatment×time inter-
action, controlling for important prognostic covariates 
(sex, age, smoking habit) and centre (stratification factor 
for randomisation). For binary outcomes at a fixed time 
point, frequencies and proportions will be calculated 
and differences tested using χ2 or Fisher’s exact tests. 
The effects of covariates will be evaluated using logistic 
regression. An ITT analysis (primary) and PP analysis 
will be performed. A cost- effectiveness analyses will be 
performed from a societal perspective, including direct 
medical and non- medical and productivity costs. Cost per 
quality- adjusted life year gained as well as costs per life 
year and costs per event- free life year gained will be calcu-
lated. The economic evaluation will be done at 5 years 
in line with the duration of the trial, and the evaluation 
will be performed in line with the Dutch guidelines for 
economic evaluations.22
Interim analysis
There will be an interim analysis at 12 months after 
the first inclusion and/or after 60 patients have been 
included, whatever comes first, and at the DSMB request. 
Formal statistical methods for evaluating interim efficacy 
and toxicity results will be used as guidelines rather than 
absolute rules. An alpha- spending function (O’Brien- 
Fleming) will be used. Reasons for DSMB decisions will 
be recorded.
Safety
The UPSIDE trial will be overseen by an international 
DSMB. The DSMB consists of clinicians (including experts 
on SSc and stem cell transplantation) and a biostatisti-
cian. Every 6 months, the DSMB will review the status and 
conduct of the clinical trial, evaluate all causes of death 
and adverse events, and make recommendations to the 
clinical research group concerning the trial’s continua-
tion and modification.
Data collection in the study will be monitored by an 
independent monitor within Julius Centre, UMC Utrecht, 
the Netherlands. There will be five scheduled visits per 
centre; the first visit will be the initiation visit, and there-
after once- a- year visits will be performed. The last visit is 
combined with the close- out visit.
Patient and public involvement
Our research question originates from clinical practice 
and a prior study that investigated patient’s experiences, 
which showed that the lack of evidence to support the 
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Table 3 Data collection
Screening Baseline 3 6 9 12 15 18 21 24 Annually
Survival status Continuous registration
Toxicity according to CTC (≥grade 3) 
and BMT- CTN (viral infections)
X X X X X X X X X X X
mRSS X X X X X X X X X X X
Laboratory
  ESR, Hb, WBC with differential, 
platelet count, C3, C4, C1q
X X X X X X X X X
  Electrolytes, renal, liver function 
tests, albumin, troponin, NT- 
ProBNP
X X X X X X X X X
  Autoantibody titres (ANA, ENA, 
ATA, ARA)
X
  Urine spot test: creatinin/protein 
ratio
X X X X
  Serology CMV, EBV, HBV, HCV, 
HIV, HSV, HTLV-1,2, VDRL, VZV
X X X X
  Immunophenotyping by FACS of 
PBMCs: CD3+, CD4+, CD8+, CD4 
CD45 RA, 
  CD4+ CD45 RO, CD3−
CD56+CD16+, CD19+, CD14+; 
IgG, IgA, IgM
X X
  Women: FSH, anti- Müllerian 
hormone
  Men: TSH, testosterone, prolactin
X X
  Blood and urine samples for 
immunological studies and ATG 
levels
X X X X X X X X
Image studies
  HR- CT X X
 
  Pulmonary function studies X X X X X X
  24- hour ECG Holter X
  Cardiac echo X X X X
  Cardiac MR X X
  Right heart catheterisation X
  18F FDG- PET scan of the thorax X X
  Nailfold capillaroscopy X X X X X X
Sampling
  Two biopsies from affected skin X       X     
Other scores
  Physician global assessment X X X X X X
  Modified HAMIS X X X X X
PROMS
  Patient global assessment X X X X X X
  SHAQ X X X X X X
  VAS X X X X X X
  EQ- 5D- 5L X X X X X X
  UCLA SCTC GIT 2.0 X X X X X X
  SFQ-28 (women) or IIEF-15 (men) X X X X X X
  FACIT X X X X X X
Continued
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decision- making process in choosing the right treat-
ment strategy is a burden for patients and caretakers.23 A 
patient panel (International Panel of Representatives of 
Patient Organizations and Patient Partners) was involved 
in the design of this study, particularly in the selection 
of outcome measures and questionnaires and develop-
ment of patient information and the consent form. Also, 
they assessed the burden of the interventions evaluated 
in this study. The panel will continue to be involved in 
the 6- monthly evaluation of the study progress and will 
support dissemination of information about the study 
among potential participants. After completion of the 
study, we intend to write a patient summary and publish 
and disseminate the results using media accessible by 
patients (including the magazine of patient organisations, 
social media and the study website). The Dutch patient 
organisation for systemic sclerosis (NVLE) recognises the 




The study will be performed according to the principles 
of the Declaration of Helsinki (adopted by the 18th World 
Medical Association (WMA) General Assembly, Helsinki, 
Finland, June 1964 and amended by the 64th WMA 
General Assembly, Fortaleza, Brazil, October 2013) and 
in accordance with the Dutch Medical Research Involving 
Human Subjects Act (WMO).
Patient information will be handled with care, taking 
into consideration the required confidentiality as stated 
by the Law for the Protection of Personal Information, 
the Dutch Medical Treatment Contracts Act, the EU 
General Data Protection Regulation and the Dutch Act 
on Implementation of the General Data Protection Regu-
lation. All data will be stored in a pseudonymised database 
(CASTOR). A limited number of people have access to 
the data. They are the principal investigator, coordinating 
investigator and data manager. Personal data are only 
processed by the researchers or by those who fall directly 
under their authority. In addition, the study monitor 
(Clinical Research Associate), auditors, employees from 
the Medical Research Ethics Committee and the Health 
Care Inspectorate of the Ministry of Health, Welfare and 
Sport have access to the source data. All are subject to the 
pledge of confidentiality. The data are directly imputed 
in CASTOR and securely stored. Research data will be 
kept up to 15 years after ending the research.
Dissemination
The results will be presented on scientific conferences 
and through publication of articles in peer- reviewed 
and patient journals. After publication of the main study 
results, the study data will be made available on request. 
The study protocol, statistical analysis plan and informed 
consent form will be made available as well (see online 
supplemental material).
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